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Introduction
Pulmonary arterial hypertension (PAH) is a devastating disease 
characterized by progressive remodeling of the pulmonary vascu-
lature. Genetic predisposition and/or environmental insult result 
in pulmonary artery endothelial cell (PAEC) apoptosis, pulmo-
nary arterial smooth muscle cell (PASMC) proliferation, occlusive 
pulmonary vascular remodeling (1–3), increased pulmonary vas-
cular resistance, and right heart failure (4). Current treatments 
are limited to pharmacological vasodilatation via the prostacy-
clin, endothelin, or nitric oxide pathways; however, proliferative 
remodeling persists and many patients require lung transplanta-
tion (5, 6). New therapeutic approaches are needed to inhibit or 
reverse vascular remodeling.
Heterozygous mutations in the bone morphogenetic protein 
receptor 2 (BMPR2) gene are present in approximately 80% of 
heritable PAH and in an estimated 20% of patients with idiopath-
ic PAH (7, 8). In the absence of a recognized mutation, reduced 
pulmonary vascular expression of BMPR2 has been identified 
in patients with both idiopathic and associated forms of PAH 
(APAH) (9), although the regulatory mechanism of this reduc-
tion remains unclear. BMPR2 expression is also reduced in mul-
tiple rodent models of PAH (10–13), providing further evidence 
of its importance in disease pathogenesis. At a cellular level, 
suppression of BMP signaling leads to reduced endothelial bar-
rier function (14, 15) and increased apoptosis of PAECs (15, 16) 
and drives proliferation (17, 18) and apoptosis resistance (19) of 
PASMCs. Endothelial-specific KO (20) and smooth muscle cell 
(SMC) expression of a dominant negative BMPR2 (21) both result 
in the development of PAH in mice. The restoration of endothe-
lial BMPR2 signaling by overexpression (22), intravenous BMPR2 
gene therapy (23, 24) or exogenous administration of elafin (25) 
reverses experimental PAH. As such, the BMPR2 signaling path-
way represents an attractive target for pharmacological interven-
tion in PAH. The specific BMPR2 agonist BMP9 (15) and clinically 
approved drugs that nonspecifically enhance BMP signaling, such 
as FK506 (26), chloroquine (27), and paclitaxel (28), have shown 
beneficial effects in experimental PAH. These studies and the 
positive clinical effect of FK506 demonstrated during compas-
sionate use (28) highlight the potential benefits of enhanced BMP 
signaling as a treatment for PAH.
MicroRNAs (miRs) are short noncoding RNAs that mediate 
posttranscriptional regulation through interactions of their seed 
region with complementary sequences in the 3′ UTR of target 
mRNA (29). Through the simultaneous repression of multiple 
targets, miRs mediate higher order regulation of cellular func-
tion. Both increased and decreased miR expression have been 
implicated in the pathology of PAH, and the therapeutic utility 
of modulating miR expression has been demonstrated in experi-
mental PAH. The investigation of miR dysregulated in human 
disease and the cellular mechanisms through which dysregulated 
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PASMC and demonstrated augmentation of BMP signaling with 
miR-140-5p mimic and SMURF1 siRNA. Finally, genetic ablation 
of Smurf1 resulted in an allele-dependent protection from experi-
mental PAH. These findings demonstrate the feasibility of target-
ing BMP signaling for the treatment of PAH.
Results
Expression of miR-140-5p is reduced in patients with PH. To study 
whole blood expression of miR in patients with disease prior to 
the initiation of drug therapy, we performed real-time quantita-
tive PCR (qPCR) array studies (TaqMan Human MicroRNA V2.0 
A, Invitrogen) on samples taken at time of diagnosis from 3 groups 
of patients with PH (idiopathic PAH [IPAH], connective tissue 
disease [CTD] with PH [CTD-PH], and chronic thromboembolic 
PH [CTEPH]) and matched control samples from healthy volun-
teers (HV) and patients with CTD with normal pulmonary artery 
pressures (Supplemental Table 1; supplemental material available 
online with this article; doi:10.1172/JCI83361DS1). Expression of 7 
miRs was decreased (miR-34a, miR-135a, miR-140-5p, miR-200c, 
miR-452-5p, miR-548-5p, and miR-758-3p), and 1 (miR-708-5p) 
was increased in patients with PH (Figure 1A). qPCR validation of 
individual patient samples demonstrated a significant downregu-
lation of miR-140-5p and miR-200c and an upregulation of miR-
708 (Supplemental Figure 1).
miR-140-5p modulates PASMC phenotype. To investigate 
the phenotypic effect of altered levels in a disease-relevant cell, 
human PASMCs were transfected with miR mimic or inhibitor to 
replicate the conditions identified in whole blood. Transfection of 
PASMCs with miR-135a inhibitor resulted in cell death. Transfec-
tion with miR-140-5p inhibitor led to increased proliferation (Fig-
ure 1, B and C) and migration (Figure 1D).
miR-140-5p is reduced in experimental models of PAH. To further 
investigate the biological relevance of downregulation of miR- 
140-5p, we examined expression in 2 experimental models of 
PAH. Consistent with previous studies, miR expression varied dur-
ing disease development in experimental models (30). However, 
the development of severe disease led to downregulation of miR- 
140-5p at day 28 in whole lung total RNA samples from animals 
with PAH induced by administration of monocrotaline (MCT) (Fig-
ure 1, E and F) and at week 14 in whole blood samples from rats with 
PAH induced by administration of the vascular endothelial growth 
factor receptor inhibitor SU5416 and hypoxia (SuHx) (Figure 1, G 
and H). Thus, consistent human disease downregulation of miR-
140-5p is a consistent finding in established experimental PAH.
miR-140-5p is reduced in patients with idiopathic PAH. To inves-
tigate the relationship between miR-140-5p and clinical severity 
of disease, levels were determined in a cohort of 20 patients with 
IPAH and 16 age-matched controls (HV) (Supplemental Table 2). 
Expression of miR-140-5p was reduced in patients at the time of 
diagnostic right heart catheterization (Figure 2A). Although there 
was overlap between groups, low levels of miR-140-5p identified 
patients with IPAH (Figure 2B) and, furthermore, identified those 
with adverse prognosis (Figure 2C). Low levels of miR-140-5p 
were also associated with indicators of increased disease sever-
ity used in clinical practice for risk stratification and treatment 
optimization (WHO functional class, exercise capacity, right atrial 
pressure, and cardiac index) (ref. 6 and Figure 2, D–G).
miRs’ effects are mediated may identify key regulators of disease 
pathology and novel therapeutic targets.
The expression of miR in experimental models of PAH is 
dependent on the time point and model examined (30). Treatment 
of patients with PAH-specific therapies alters signaling in disease-
relevant pathways (31). To exclude the effect of PAH-specific drug 
therapy on cell signaling and minimize variation in the clinical dis-
ease state, we examined whole blood miR expression in patients at 
the time of diagnosis with PAH prior to the initiation of drug thera-
py. We identified downregulation of miR-140-5p, a tumor-suppres-
sor miR that regulates cellular proliferation and migration, reduced 
levels of which have been reported in patients with hepatocellular 
carcinoma (32) and lung (33) and breast cancer (34, 35). Consistent 
with our clinical findings, levels of miR-140-5p were reduced at lat-
er time points in experimental models of PAH. miR-140-5p inhibi-
tor increased proliferation and migration of PASMCs, suggesting a 
potential therapeutic role for miR-140-5p mimic and implicating key 
derepressed targets in disease pathology. Delivery of miR-140-5p 
mimic prevented the development of experimental PAH and atten-
uated the progression of established disease. Bioinformatic analy-
sis identified BMP signaling as a pathway altered by miR-140-5p 
and highlighted a number of targets with known and previously 
undetermined roles in disease pathology. SMAD-specific E3 ubiq-
uitin protein ligase 1 (SMURF1), an E3 ubiquitin ligase that targets 
BMPR2 and downstream signaling mediators for proteasomal deg-
radation, was central within the network of pulmonary hyperten-
sion–related (PH-related) miR-140-5p targets and had the highest 
conserved predicted binding site, with miR-140-5p. Expression 
of SMURF1 was increased in whole blood samples of treatment-
naive patients with PAH and SMURF1 immunoreactivity increased 
within the remodeled pulmonary vasculature of patients with heri-
table and APAH. The role of SMURF1 in the development of PAH 
is unknown, and its binding site with miR-140-5p is unvalidated. 
We therefore validated the miR-140-5p/SMURF1-binding site in 
Figure 1. miR-140-5p is reduced in patients with PH and animal models 
of PAH and modulates PASMC phenotype. (A) Heat map representing 
differentially expressed whole blood miR in treatment-naive patients with 
PH and control groups (fold change > 2, comparison between patients with 
PH and control groups, n = 4 per group). (B) Effect of whole blood miR on 
PASMC proliferation in vitro. PASMCs were transfected with miR mimic, 
inhibitor (Inh), or scramble control (SCR) and proliferation assessed at 72 
hours. Inhibition of miR-135a led to cell death, and inhibition of miR- 
140-5p led to increased proliferation (n = 5, *P < 0.05, 1-way ANOVA with 
Dunnett’s post-test correction, mean ± SEM). (C and D) PASMC prolif-
eration (C) and migration (D) following miR-140-5p mimic and inhibitor 
transfection at 72 and 6 hours, respectively. miR-140-5p inhibitor led to 
increased proliferation and migration in comparison with both SCR and 
miR-140-5p mimic (C: n = 5, D: n = 4, C and D: *P < 0.05, **P < 0.01, 1-way 
ANOVA with Tukey’s post-test correction, mean ± SEM, photomicrographs 
representative of n = 5 (C), and n = 4 (D). Original magnification, ×10 (C); 
×20 (D). (E and F) miR-140-5p is reduced during development of PAH in 
the MCT rat model. RVSP (E) is increased and miR-140-5p (F) decreased at 
day 28 following injection of 60 mg/kg MCT in the Sprague-Dawley rat (E 
and F, n = 5–8 per group, *P < 0.05, 2-way ANOVA with Tukey’s post-test 
correction, mean ± SEM). (G and H) miR-140-5p is reduced during the 
development of PAH in the SuHx rat model. RVSP is increased and miR-
140-5p decreased at week 14 following injection with 20 mg/kg Su5416 and 
3 weeks of 10% O2 in the Wistar-Kyoto rat (G and H: n = 8 per group,  
*P < 0.05, 2-way ANOVA with Tukey’s post-test correction, mean ± SEM).
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area (Figure 3G), which was associated with fewer proliferating cell 
nuclear antigen–positive (PCNA-positive) cells within the media of 
remodeled pulmonary arterioles (Figure 3E).
Treatment with nebulized miR-140-5p mimic attenuates established 
disease in 2 experimental models of PAH. Data presented thus far offer 
evidence that miR-140-5p modulates PASMC phenotype in vitro 
and prevents disease development in the MCT rat. We next inves-
tigated whether miR-140-5p mimic would alter the progression of 
established disease in both the MCT and SuHx rat models of PAH.
First, animals were injected with MCT and allowed to devel-
op PAH over 21 days prior to experimentation (Figure 4A). The 
presence of disease was confirmed by echocardiography (Figure 
4B), and animals were randomly assigned to blinded treatment 
groups receiving nebulized delivery of miR-140-5p mimic or 
scramble control miR (Figure 4A). Hemodynamic and patho-
logical parameters in all groups indicated development of PAH. 
However, the miR-140-5p mimic–treated group had an increased 
PAAT (Figure 4B) and reduced RVSP (Figure 4C) and right ven-
tricular hypertrophy (RVH) (Figure 4D) compared with scramble 
control miR–treated animals, indicating therapeutic effect on 
established MCT-induced PAH. Confirming delivery, levels of 
Treatment with nebulized miR-140-5p mimic prevents the develop-
ment of experimental PAH. miR-140-5p expression was decreased 
with the development of disease in the MCT rat model of PAH (Fig-
ure 1, E and F). To explore whether miR-140-5p mimic would pre-
vent the development of disease phenotype, rats were injected with 
MCT and randomly assigned to blinded treatment groups receiv-
ing nebulized delivery of miR-140-5p mimic or scramble control 
miR at days 0, 7, and 14 (Figure 3A and ref. 36). Rats treated with 
scramble control miR developed PAH as defined by decreased pul-
monary artery acceleration time (PAAT) (Figure 3B) and elevated 
right ventricular systolic pressure (RVSP) (Figure 3C). The miR-
140-5p mimic–treated group had a longer PAAT (Figure 3B) and 
reduced RVSP (Figure 3C). There were no significant differences 
in left ventricular hemodynamics between groups (Supplemental 
Table 3). Confirming delivery, levels of miR-140-5p were increased 
in whole lung RNA extract of mimic-treated animals at the time of 
catheterization. However, levels 1 week after the final nebulized 
dose were lower than those in control Sprague-Dawley rats (Figure 
3D). miR-140-5p mimic–treated rats also showed a reduction in the 
degree of pulmonary vascular remodeling (Figure 3E), as measured 
by vessel muscularization (Figure 3F), and media to cross-sectional 
Figure 2. miR-140-5p is reduced in patients with IPAH. (A) Lower whole blood levels of miR-140-5p were observed in patients with IPAH when compared 
with HV (IPAH, n = 20, HV, n = 16, **P < 0.01, unpaired 2-tailed Student’s t test, mean ± SEM). (B) Receiver operating characteristic (ROC) curve showing 
sensitivity and specificity of whole blood miR-140-5p levels for discriminating patients with PAH from HV at time of diagnosis (IPAH, n = 20, HV,  
n = 16, area under ROC curve = 0.74, P = 0.0171). (C) Kaplan-Meier analysis of survival, stratified by ROC-derived miR-140-5p cut-off. Survival in patients 
with miR-140-5p levels above the cut-off is indicated by the solid line and survival in patients with levels below by the dashed line. The table beneath the 
graph indicates numbers at risk over time in years (IPAH, n = 20, HV, n = 16, *P < 0.05, log-rank [Mantel-Cox] test). (D–G) Reduced levels of miR-140-5p are 
present in patients with increasing clinical severity of PAH: WHO class (D), incremental shuttle walk test distance (ISWT) (E), right atrial pressure (RAP) 
(F), and cardiac index (G) (D–G: IPAH, n = 20, HV, n = 16, *P < 0.05, 1-way ANOVA with Dunnett’s post-test correction, mean ± SEM).
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nary vasculature (Supplemental Figure 2). However, levels 1 week 
after the final nebulized dose were lower than those in control 
Wistar Kyoto rats (Figure 5E). As demonstrated in both MCT stud-
ies, miR-140-5p mimic–treated rats also showed a reduction in the 
degree of pulmonary vascular remodeling (Figure 5, F–H).
miR-140-5p regulates key mediators of PAH pathogenesis. Path-
way analysis of miR-140-5p targets identified overrepresentation 
in pathways related to PAH pathology (Supplemental Table 6). To 
refine potential target genes downstream of miR-140-5p that may 
be specifically involved in the pathogenesis of PAH, we identified 
targets within a PH-related gene network (refs. 37, 38, and Supple-
mental Table 7). The predicted miR-140-5p network includes key 
genes regulating multiple points in the TGF-β superfamily (Figure 
6A, Supplemental Table 8, and Supplemental Figure 3). Regula-
tion of a target mRNA by an miR requires temporal and spatial 
coexpression. We therefore tested predicted miR-140-5p–target 
interactions in PASMCs. Transfection with miR-140-5p inhibitor 
increased, and mimic decreased, mRNA and protein expression of 
TGF-β receptor 1 (ALK5), platelet-derived growth factor receptor α 
(PDGFRA) and SMURF1, validating bioinformatic predictions in a 
disease-relevant cell (Figure 6, B and C).
SMURF1 is increased in patients with PAH, and levels are regu-
lated by miR-140-5p. Within the miR-140-5p PH–related gene 
miR-140-5p were increased in whole lung RNA extract of mimic-
treated animals at time of catheterization. However, levels 1 week 
after the final nebulized dose were lower than those in control 
Sprague-Dawley rats (Figure 4E). No significant changes in left 
ventricular hemodynamics were observed (Supplemental Table 
4). miR-140-5p mimic–treated rats also showed a reduction in the 
degree of pulmonary vascular remodeling (Figure 4, F–H).
Second, animals were treated with SU5416 and 3 weeks of 
hypoxic exposure followed by a further 5 weeks in normoxic con-
ditions prior to experimentation (Figure 5A). The presence of dis-
ease was confirmed by echocardiography (Figure 5B), and animals 
randomly assigned to blinded treatment groups received nebulized 
delivery of miR-140-5p mimic or scramble control miR (Figure 5A). 
Hemodynamic and pathological parameters in all groups indicated 
development of PAH. However, animals treated with miR-140-5p 
mimic had an increased PAAT (Figure 5B) and reduced RVSP (Fig-
ure 5C) and RVH (Figure 5D) compared with scramble control 
miR–treated animals, indicating a therapeutic effect on established 
SuHx-induced PAH. No significant changes in left ventricular 
hemodynamics were observed (Supplemental Table 5). Confirm-
ing delivery, levels of miR-140-5p were increased in whole lung 
RNA extract of mimic-treated animals at the time of catheteriza-
tion (Figure 5E), and Cy3-labeled probe was detected in the pulmo-
Figure 3. miR-140-5p prevents the development of PAH in the MCT rat model. (A) Experimental time line. (B) PAAT at days 0 and 21. (C) RVSP at day 21. (D) 
qPCR showing whole lung miR-140-5p levels at day 21. (E) Representative photomicrographs of lung sections from SCR and miR-140-5p mimic–treated ani-
mals at day 21. Sections stained with Alcian blue EVG, α–smooth muscle actin (SMA), vWF, and PCNA (photomicrographs representative of n = 7–8 per group). 
Original magnification, ×200. Scale bars: 50 μm. (F and G) Pulmonary vascular remodeling by percentage muscularized vessels (F) and medial wall thickness as 
a ratio of total vessel size (media/CSA) (G) (B–G: n = 7–8 per group, *P < 0.05; **P < 0.01; ***P < 0.001, 2-tailed Mann-Whitney U test, mean ± SEM).
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network, the most connected protein and the target with the 
greatest preferentially conserved targeting score was SMURF1 
(Figure 6A, Supplemental Tables 9 and 10, and ref. 39). Whole 
lung SMURF1 protein correlated inversely with miR-140-5p 
(Figure 6D) in experimental studies, suggesting a regulatory 
interaction. Further increasing confidence in SMURF1 as an 
important mediator of disease pathology, SMURF1 mRNA was 
increased in whole blood from treatment-naive patients at the 
time of diagnosis with PAH (Figure 6E) and SMURF1 protein 
immunoreactivity increased within endothelial and SMCs of 
pulmonary vascular lesions of explanted lungs from patients 
with BMPR2 mutation–associated heritable PAH and associ-
ated PAH (Figure 6F).
miRs mediate posttranscriptional regulation by direct bind-
ing of sequences analogous to their seed region in the 3′ UTR of 
target mRNA (Figure 6G). To demonstrate direct targeting of the 
SMURF1 3′ UTR by miR-140-5p, we transfected PASMCs with 
a plasmid containing a luciferase-SMURF1 3′ UTR construct. 
Cotransfection with miR-140-5p mimic or inhibitor increased and 
decreased luciferase activity, respectively (Figure 6, H and I).
miR-140-5p and SMURF1 modulate BMP signaling in PASMCs. 
The data presented thus far provide evidence that reduced levels 
of miR-140-5p contribute to the pathogenesis of PAH through 
derepression of key cellular targets. Target prediction and network 
analysis identified SMURF1 as a key miR-140-5p target and as a 
regulator of BMP signaling in PAH.
Figure 4. miR-140-5p attenuates experimental PAH in the MCT rat model of PAH. (A) Experimental time line. (B) PAAT at days 0, 21, and 35. (C) RVSP at 
day 35. (D) RVH at day 35. (E) qPCR showing whole lung miR-140-5p levels at day 35. SD, Sprague-Dawley; S, SCR; M, mimic. (F) Representative pho-
tomicrographs of lung sections from SCR and miR-140-5p mimic–treated animals at day 35. Sections stained with Alcian blue EVG, α-SMA, and PCNA 
(photomicrographs representative of n = 7–8 per group). Original magnification, ×200. Scale bars: 50 μm. (G and H) Pulmonary vascular remodeling by 
percentage of muscularized vessels (G) and medial wall thickness as a ratio of total vessel size (media/CSA) (H) (B–H: n = 7–8 per group, *P < 0.05, 2-tailed 
Mann-Whitney U test, mean ± SEM).
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Reduced BMP signaling is a common pathological finding in 
PAH, and augmentation of this pathway may provide therapeutic 
benefit. Our network and pathway analysis (Supplemental Tables 
2 and 4 and Supplemental Figure 3) indicated that both miR- 
140-5p and SMURF1 regulate BMP signaling, activity that is indi-
cated by expression of the transcription factor inhibitor of differ-
entiation 1 (ID1) (40). To demonstrate modulation of BMP signal-
ing by SMURF1 and miR-140-5p, PASMCs were transfected with 
nontargeting siRNA or siRNA to SMURF1 and SCR or miR-140-5p 
mimic prior to stimulation with BMP4. SMURF1 siRNA and miR-
140-5p mimic both increased BMP4-mediated signaling, as dem-
onstrated by increased expression of ID1 protein (Figure 7A) and 
increased activity of an ID1 promoter luciferase construct (BMP 
response element [BRE]) (Figure 7, B and C).
Genetic ablation of Smurf1 prevents the development of PAH. 
SMURF1 is increased in patients with PAH, is regulated by miR-
140-5p, and regulates BMP signaling in PASMCs. To investigate 
the role of SMURF1 in the development of PAH, we studied the 
effect of genetic deletion of Smurf1 in C57BL/6 mice exposed to 
SuHx. Loss of Smurf1 resulted in an allele-dependent protection 
from the development of PAH as shown by reduced RVSP (Figure 
7D), RVH (Figure 7E), and lung remodeling (Figure 7F), demon-
strating the critical importance of SMURF1 in PAH pathogenesis.
Discussion
The present study is the first, to our knowledge, to identify 
downregulation of miR-140-5p in treatment-naive patients and 
experimental models of PAH. Treatment with miR-140-5p mimic 
Figure 5. miR-140-5p attenuates experimental PAH in the Sugen hypoxic rat model of PAH. (A) Experimental time line. (B) PAAT at weeks 0, 8, and 11. (C) 
RVSP at week 11. (D) RVH at 11 weeks. (E) qPCR showing whole lung miR-140-5p levels at 11 weeks. (F) Representative photomicrographs of lung sections from 
SCR and miR-140-5p mimic–treated animals at 11 weeks. Sections stained with Alcian blue EVG, α-SMA, and PCNA (photomicrographs representative of  
n = 5–7 per group). Original magnification, ×200. Scale bars: 50 μm. (G and H) Pulmonary vascular remodeling by percentage of muscularized vessels (G) and 
medial wall thickness as a ratio of total vessel size (media/CSA) (H). (B–H: n = 5–7 per group, *P < 0.05, **P < 0.01, 2-tailed Mann-Whitney U test, mean ± SEM).
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Genetic restoration of BMPR2 attenuates both chronic hypox-
ia and MCT-induced PAH (23, 24). The selective BMP agonist 
BMP9 (15) and drugs that nonspecifically enhance BMP signal-
ing, such as FK506 (26), chloroquine (27), and paclitaxel (28), 
have shown beneficial effects in preclinical models. Early stud-
ies of FK506 have shown clinical effect during compassionate 
use in patients with PAH. An alternative approach to enhancing 
BMP signaling may be through inhibition of negative regulators 
of the pathway (27). SMURF1 negatively regulates BMP signaling 
through ubiquitination and proteasomal degradation of BMPR2 
(47), type I BMP receptors, and downstream signaling mediators 
(48). Through human array data and bioinformatic prediction, we 
have identified miR-140-5p and SMURF1 as 2 means of modulat-
ing BMP signaling in PAH.
miR-140-5p is considered a tumor suppressor miR, down-
regulation of which has been identified in a number of neoplastic 
conditions (32–35). Loss of miR-140-5p led to increased cellular 
proliferation and migration through derepression of previously 
validated targets, including PDGFRA (49), type 1 IGF recep-
tor (IGF1R) (33), ALK5, and FGF2 (32). miR-140-5p is known to 
play a critical role in bone and skeletal development, mediating 
downstream effects of IL-1β and TGF-β through interactions with 
ADAM metallopeptidase with thrombospondin type 1 motif 5 
(ADAMTS5) (50) and SP1 transcription factor (SP1) (51). Further-
more, the rs7205289 single-nucleotide polymorphism is associ-
ated with nonsyndromic cleft palate and alters processing of pre–
miR-140, resulting in reduced expression of miR-140-5p.
Locked nucleic acid structures are deliverable and stable 
in the circulation, providing an effective means of anti-miR or 
antagomiR therapy. The clinical application of such miR-based 
therapies has shown significant promise (52). In 3 experimen-
tal models of PAH, we demonstrate that increased miR-140-5p 
prevents disease development and attenuates the progression 
of established disease. However, administration of miR-140-5p 
mimic did not fully reverse established disease. This may be attrib-
utable to a number of factors: the disease phenotype developed in 
therapeutic studies was severe; nebulized delivery of miR-140-5p 
provided incomplete restoration of whole lung levels compared 
with those in untreated animals; and modulation of a large num-
ber of mRNA by delivery of a single miR will result in repression 
of those with both positive and negative effects on disease phe-
notype. Furthermore, the development of pre-miR or miR mimic 
technology has lagged behind that of anti-miR therapy (53), and 
for these reasons, we sought to identify molecules downstream of 
miR-140-5p as therapeutic targets. We demonstrate in vitro that 
miR-140-5p regulates expression of SMURF1 through direct inter-
action with the 3′ UTR and that both miR-140-5p and SMURF1 
modulate BMP signaling in PASMCs.
SMURF1 is a homologous to the E6-AP carboxyl termi-
nus–type (HECT-type) ubiquitin ligase that acts as a negative 
regulator of BMP signaling via ubiquitination and subsequent 
proteasomal degradation of SMAD1, SMAD5 (48), and BMPR2 
(47). SMURF1 regulates cell migration and adhesion modulating 
signaling downstream of BMP (47, 48), TGF-β, and IFN-γ (54), 
and amplification of SMURF1 has been observed and impli-
cated in human pancreatic cancer (55). Expression of SMURF1 
is increased in animal models of PAH (47). We demonstrate 
improved disease phenotype in experimental PAH via modulation 
of key cellular targets. Network analysis identified the E3 ubiqui-
tin ligase SMURF1 as a potential central regulator of PH-related 
miR-140-5p targets and BMP signaling. SMURF1 whole blood 
mRNA and pulmonary vascular SMURF1 protein expression 
were increased in patients with PAH, providing further evidence 
of a role in human disease pathology. The critical importance of 
SMURF1 in the development of PAH was demonstrated by genetic 
deletion of Smurf1, which provided an allele-dependent protec-
tion from experimental disease. Thus, the interaction between 
miR-140-5p and SMURF1 represents a mechanism by which BMP 
signaling may be reduced in patients with PAH without an iden-
tifiable BMPR2 mutation, and inhibition of SMURF1 provides a 
mechanism by which BMP signaling may be augmented for thera-
peutic benefit in patients with PAH.
Recent years have seen significant advances in the treat-
ment of PAH; however, there remains no pharmacological cure 
for this devastating disease (41, 42). Therapeutic options are 
limited to vasodilatation via the prostacyclin, endothelin, or 
nitric oxide pathways; however, proliferative remodeling con-
tinues, and normalization of pulmonary vascular resistance 
with long-term improvement is rarely achieved. Targeting the 
proliferation that drives disease pathology is an attractive con-
cept. Excellent proof of concept for this strategy is provided by 
the positive preclinical (43) and clinical (44, 45) hemodynamic 
effects of imatinib, although clinical approval was limited by an 
adverse side effect profile.
Impaired BMP signaling, through gene mutation or envi-
ronmental insult, is a consistent finding in human (7–9, 46) and 
experimental PAH (10, 11). BMPR2 mutation results in haploin-
sufficiency of the receptor and reduced pathway activity; how-
ever, penetrance is incomplete, and not all patients with the muta-
tion have disease. It has been proposed that in the presence of a 
BMPR2 mutation, further pathway suppression is required for 
disease development, and in the absence of BMPR2 mutation, the 
mechanism by which signaling is reduced remains unclear.
Figure 6. miR-140-5p regulates key mediators of PAH pathology. (A) 
Predicted PH-related direct targets of miR-140-5p. (B and C) qPCR (B) and 
protein expression by Western blot (C) showing expression of miR-140-
5p targets ALK5, PDGFRA, and SMURF1 in PASMCs at 72 hours follow-
ing transfection with miR-140-5p mimic (M), miR-140-5p inhibitor (I), or 
scramble control (S) (B: n = 6, C: n = 5, B and C: *P < 0.05; **P < 0.01;  
***P < 0.001; ****P < 0.0001, 1-way ANOVA with Tukey’s post-test cor-
rection, mean ± SEM). (D) Whole lung levels of SMURF1 protein correlate 
inversely with miR-140-5p (n = 38, P < 0.05, r = –0.36, Spearman rank). (E) 
Increased whole blood levels of SMURF1 mRNA were observed in patients 
with IPAH when compared with HV (IPAH n = 20, HV n = 16, *P < 0.05, 
unpaired 2-tailed Student’s t test, mean ± SEM). P, prevention; T, thera-
peutic. (F) Representative photomicrographs demonstrating immunore-
activity of SMURF1 in endothelial and SMCs of pulmonary vascular lesions 
in the transplanted lungs of patients with BMPR2 mutation–associated 
heritable PAH, associated PAH, and non-PAH control lung (photomicro-
graphs representative of n = 26: APAH n = 8, IPAH n = 8, FPAH, n = 6, con-
trol n = 4). Original magnification, ×200 (hereditary PAH and control); ×400 
(associated PAH). Scale bars: 50 μm. (G) Chromosomal location of putative 
miR-140-5p–binding site in the 3′ UTR of SMURF1. (H and I) Transfection 
of PASMCs with miR-140-5p inhibitor (H) and mimic (I) alter luciferase 
activity of SMURF1 3′ UTR construct at 24 hours (H and I: n = 4, **P < 0.01, 
****P < 0.0001, 2-tailed Mann-Whitney U test, mean ± SEM).
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Methods
Patient groups and study design
For TaqMan miR array studies, RNA was extracted from individual 
patient samples and quantified as described below. Samples were 
pooled by clinical diagnosis (n = 4 per group: IPAH, CTD-PH, CTEPH). 
The 2 control groups used were as follows: group 1: HV; group 2: 
patients with CTD referred for investigation for PH, but found to have 
normal pulmonary hemodynamics (n = 4 per group: HV and CTD). 
Validation of array findings was undertaken by 2 means: single-sample 
qPCR assay of individual patient samples from those used in array and 
single-sample qPCR assay of individual patient samples from a sec-
ond cohort of patients with IPAH and HV. Clinical details of patients 
included are provided in Supplemental Tables 1 and 2.
Examination of SMURF1 expression in explanted lungs was 
undertaken using patient samples from the Papworth NHS Founda-
tion Trust Hospital Tissue Bank samples. PAH lung and control tis-
sues were formalin-fixed, paraffin-processed wax block samples that 
were returned to the Tissue Bank after sectioning (associated PAH, 
n = 8; idiopathic PAH, n = 8; familial PAH, n = 6, and control, n = 4). 
increased expression of SMURF1 mRNA in whole blood and 
SMURF1 protein immunoreactivity within pulmonary vascu-
lar lesions from patients with PAH. Consistent with our clinical 
findings and bioinformatic predictions, reduced levels of miR-
140-5p lead to derepression of SMURF1 in vitro, and both miR-
140-5p mimic and inhibitor alter expression of SMURF1 (mRNA, 
protein, and 3′ UTR reporter construct) in PASMCs, validating 
the interaction in a disease-relevant cell.
SMURF1 is a key negative regulator of the BMP pathway, and 
the effect of small alterations in cellular levels has an amplified 
effect on downstream signaling and cell phenotype. The critical 
importance of SMURF1 to the development of experimental PAH 
is demonstrated by the allele-dependent protection provided by 
genetic deletion in the SuHx model.
The identification of small molecule inhibitors of SMURF1 
(56) offers the opportunity to target negative regulators of BMP 
signaling as a strategy for antiproliferative treatments of PAH. 
Furthermore, our data suggest that whole blood miR-140-5p and 
SMURF1 levels may be used to identify patients with abnormal 
signaling in this pathway.
Figure 7. miR-140-5p and SMURF1 modulate BMP signaling in vitro, and SMURF1 is critical to the development of experimental PAH. (A–C) miR-140-5p 
mimic and SMURF1 siRNA augment BMP signaling in vitro. (A) PASMCs were transfected with SCR and miR-140-5p mimic or NTsiRNA and SMURF1 siRNA 
prior to stimulation with BMP4. At 72 hours, expression of native ID1 protein was increased in miR-140-5p mimic– and SMURF1 siRNA–treated cells (n = 4, 
mean ± SEM). (B) PASMCs were cotransfected with BRE construct and SCR or miR-140-5p prior to stimulation with BMP4. At 24 hours, BRE activity was 
increased in miR-140-5p mimic–treated cells. (C) PASMCs were cotransfected with BRE construct and NTsiRNA or SMURF1 siRNA prior to stimulation with 
BMP4. At 24 hours, BRE activity was increased in SMURF1 siRNA–treated cells. (B and C: n = 4, *P < 0.05, 2-tailed Mann-Whitney U test, mean ± SEM). (D–F) 
Genetic ablation of SMURF1 confers protection from PAH in the SuHx mouse model. (D) RVSP at week 3. (E) RVH at week 3. (F) Vessel muscularization at 
week 3. (D–F: n = 11–13 per group, *P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001, 1-way ANOVA with Tukey’s post-test correction, mean ± SEM).
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Western immunoblotting
Sample (40 μg) was loaded on a 4% to 12% Bis-Tris NuPage gel, run 
under reducing conditions in MOPS running buffer (Invitrogen), and 
transferred to a nitrocellulose membrane (Invitrogen). Membranes 
were blocked (blocking buffer, LI-COR Biosciences) for 90 minutes 
at room temperature, then incubated with ALK5 (1:500, ab31013, 
Abcam), ID1 (1:1000, clone 195-14, CalBioreagents), PDGFRA (1:250, 
ab61219, Abcam), SMURF1 (1:250, Ab57573, Abcam), or GAPDH anti-
body (1:1000, 14C10, Cell Signaling Technology) overnight at 4°C 
with Quick Western IRDye (LI-COR Biosciences) prior to a reading at 
700 nm on an Odyssey SA imaging system (LI-COR Biosciences).
Target prediction
miR target prediction was performed using the TargetScan 6.2 (con-
served) algorithm (39), which identifies mRNA transcripts with con-
served complementarity to the miR “seed sequence” (nucleotides 2–7) 
and biologically validated interactions. Functional annotation was 
performed using the Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) (60).
PH-related miR-140-5p targets were identified using a curated 
set of PH-relevant genes (Supplemental Table 6). These genes were 
selected based on their cooccurrence with the search term “pulmonary 
hypertension” in the PubMed database (37). Interactions between net-
work genes were annotated according to a list of protein-protein inter-
actions (61–63), protein-DNA interactions (64), and kinase-substrate 
interactions (65) drawn from consolidated databases.
Animal studies
MCT rat studies. PAH was induced in male Sprague-Dawley rats 
(Charles River Laboratories) weighing 200–210 g by a single subcuta-
neous injection of MCT (Sigma-Aldrich) at 60 mg/kg. For time-course 
experiments, animals were sacrificed at days 2, 7, and 28. Preventative 
intervention was performed at days 0, 7, and 14 and animals sacrificed 
at day 21. Therapeutic intervention was performed at days 21 and 28 
and animals sacrificed at day 35.
Sugen hypoxia rat studies. PAH was induced in male Wistar Kyoto 
(Harlan) rats weighing 200-230 g by a single subcutaneous injection 
of SU5416 (Tocris) at 20 mg/kg, followed by housing at 10% O2 and 
5% CO2 for 3 weeks and normoxia for remaining weeks. For time-
course experiments, animals were sacrificed at 3, 5, 8, and 14 weeks. 
Therapeutic experimentation was undertaken at 8, 9, and 10 weeks, 
with sacrifice at 11 weeks.
SuHx Smurf1 mouse studies. Smurf1 KO (Smurf1−/−) mice were 
obtained under license from Y. Zhang (Laboratory of Cellular and 
Molecular Biology, Center for Cancer Research, National Cancer Insti-
tute, Bethesda, Maryland, USA) (66). Smurf1−/− mice were crossed with 
WT C57BL/6 mice to generate SMURF1 heterozygotes (Smurf1+/−), 
which were subsequently crossed to generate Smurf1−/− and littermate 
controls. Mice were administered SU5416 (Sigma-Aldrich) at 20 mg/
kg once weekly under normoxia or hypoxia as described previously 
(67). At study termination, mice were sacrificed and PAH pathology 
was assessed as described previously (12).
Where stated, in vivo transfection was performed with 20 μM of miR-
140-5p mimic or scramble control (Invitrogen) using Invivofectamine 2 
(Invitrogen) delivered by MicroSprayer Aerosolizer (Penn-Century Inc.). 
Transfection efficiency was assessed by qPCR and tissue distribution 
assessed by delivery of Cy3-labeled scramble control (20 μM, Invitrogen).
Control tissue comprised cases of unused donor lung and tissue from 
lobes of lung clear of tumor taken from pneumonectomy specimens. 
Lungs were inflated using a pressure-limited pump with peribronchial 
neutral-buffered 10% formalin solution (Genta Medical) and fixed 
for at least 24 hours; sections were examined macroscopically by a 
pathologist, and representative tissue blocks were taken for micro-
scopic examination.
Whole blood RNA extraction and quantification
Blood samples were drawn in Tempus whole blood tubes (Applied Bio-
systems) at the time of diagnosis from patients with PH and matched 
control participants. Total RNA (miR and mRNA) was extracted using 
an miR/mRNA extraction kit (Promega) on the Maxwell platform 
(Promega). mRNA purity and concentration were assessed by Nano-
drop (Thermo Fisher Scientific).
TaqMan low-density array of miR
miRs were reverse transcribed to single-stranded cDNA using the Taq-
Man microRNA Reverse Transcription Kit (Invitrogen). Reverse tran-
scribed products from individual samples were pooled and expression 
quantified on TaqMan Human MicroRNA V2.0 A (Invitrogen). miR lev-
els were normalized to U6 and analyzed by fold change in HTqPCR (57).
TaqMan PCR
Expression of miR and mRNA was determined by PCR using Taq-
Man Small RNA Assay (U6, 001973 and miR-140-5p 001187, Invitro-
gen) or TaqMan Gene Expression Assay (18S, HS03003631_g1; ID1, 
Hs03676575_s1; SMURF1, Hs00410929_m1; RUNX2, HS00231692_
m1, Invitrogen). miR and mRNA levels were normalized to U6 and 
18S, respectively, for quantification using the ΔΔCt comparative quan-
tification method as previously described (13).
Cell culture and phenotypic assays
Human PASMCs (Lonza) were maintained as previously described 
(58). Before stimulation, PASMCs were synchronized by incubating 
in DME medium containing PSA Solution (Invitrogen) and 0.2% 
fetal bovine serum for 48 hours. Cell proliferation was quantified 
by DNA staining (LI-COR Biosciences) and migration using a Boy-
den chamber assay (59). Where stated, cells were transfected with 
miR-140-5p mimic, inhibitor, or scramble control (Invitrogen) or 
SMURF1 siRNA (Dharmacon) using HappyFect (Tecra), and stim-
ulated with 20 ng/ml recombinant human PDGFBB or 10 ng/ml 
BMP4 (R&D Systems) in DME medium containing PSA solution 
(Invitrogen) in 0.2% fetal bovine serum.
Luciferase
PASMCs were transfected with 100 ng of plasmid vector (SMURF1 
3′ UTR, HmiT055054-MT01, Genecopia; pGL4 luc2p/ID1/Hygro, 
Promega pRL-TK, Promega) with miR-140-5p mimic, inhibitor, or 
scramble control (Invitrogen) or SMURF1 siRNA (Dharmacon) per 
the manufacturer’s instructions. Twenty-four hours after transfection, 
cells were harvested and lysed and luciferase reporter activities mea-
sured using the Dual-Glo Luciferase Assay System (Promega). Firefly 
luciferase activity was normalized to Renilla luciferase activity. For 
BMP activity assays, cells were stimulated with BMP4 (R&D Systems) 
at 50 ng/ml in DME medium containing PSA solution (Invitrogen) in 
0.2% fetal bovine serum.
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2-tailed Student’s t test, Mann-Whitney U test, or ANOVA with post-test 
correction as appropriate. P < 0.05 was considered statistically significant.
Study approval
Human samples. All subjects gave informed written consent, and the 
study was approved by the Yorkshire and the Humber – Sheffield 
Research Ethics Committee and the Sheffield Teaching Hospitals Foun-
dation Trust Observational Cardiovascular Biobank (08/H1308/193 
and STH15222).
Animal studies. All animal experiments were approved by the 
University of Sheffield Project Review Committee and conformed to 
United Kingdom Home Office ethical guidelines.
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Animals were monitored for signs of distress and right heart failure, 
defined by loss of body weight (either >5%/24 hours or >10%/48 hours), 
lethargy, and respiratory distress, as previously described (68, 69).
Echocardiography, cardiac catheterization, and RVH. Echocardiog-
raphy was performed at baseline and sacrifice in prevention studies 
and at baseline, pretreatment, and sacrifice in therapeutic studies 
(Vivo 770, Visualsonics). Closed chest cardiac catheterization (Millar) 
was performed at sacrifice in time-course and intervention studies. 
Echocardiography, cardiac catheterization, and measurement of RVH 
were performed as previously described (59).
Rodent miR/mRNA extraction and quantification
Total RNA (miR and mRNA) was extracted using an miR/mRNA 
extraction kit (Promega) on the Maxwell platform (Promega). mRNA 
purity and concentration were assessed by Nanodrop (Thermo Fisher 
Scientific). PCR was performed as described above.
Rodent protein extraction and quantification
Whole-lung segments were snap-frozen, then ground under liquid 
nitrogen. Powder was stored at –80°C prior to extraction with T-PER 
Tissue Protein Extraction Reagent (Thermo Scientific). Western 
immunoblotting was performed as described above.
Immunohistochemistry
Lung tissue was harvested, processed. and stained as previously 
described (59). Paraffin-embedded sections (5 μm) were stained 
for Alcian blue elastin van Gieson (EVG) and H&E. Immunohisto-
chemical staining used antibodies against SMA (M0851; Dako) to 
visualize SMCs and von Willebrand Factor (vWF; A0082, Dako) to 
visualize endothelial cells. SMURF1 (ab57573, Abcam) was used 
to localize protein expression within pulmonary vascular lesions. 
Mouse anti–human PCNA antibody (M0879; Dako) was used to 
assess proliferation. Species-appropriate biotinylated secondary 
antibody (1:200) with Avidin Biotin Enzyme Complex (Vectastain 
kit, Vector Laboratories) or species-appropriate florescent anti-
body was used (Alexa Fluor 488 dye, Thermo Fisher Scientific) was 
used. Microscopy was performed on the Axiocam 506 Color System 
(Zeiss) and analysis undertaken in Zen 2 Blue Edition (Zeiss).
Quantification of pulmonary vascular remodeling
Pulmonary vascular remodeling was quantified by assessing the 
degree of muscularization and the percentage of affected pulmonary 
arteries and arterioles in 3 groups based on vessel size: small pulmo-
nary arterioles with a diameter less than 50 μm, medium pulmonary 
arteries with a range in diameter from 51 to 100 μm, and large pulmo-
nary arteries with a diameter greater than 100 μm (13, 59).
Statistics
Statistical analysis was performed as stated in Prism 6.0h for Macintosh 
(GraphPad Software). Normality of data distribution was assessed by Kol-
mogorov-Smirnov test and differences between groups determined by 
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